Hyperkalemia, a serious condition characterized by elevated potassium levels, is associated with increased risk of mortality, and is frequently prevalent and recurrent in patients who suffer from heart failure (HF). Certain factors—such as comorbid illnesses and use of medicines that are important for HF outcomes but elevate potassium levels—can increase the chronic risk for hyperkalemia. Weighing the risk of hyperkalemia against the risk of discontinuing cardio-protective therapies can present a paradox to clinicians treating HF patients. Although the short-term management of hyperkalemia can be effective, long-term management can be challenging. New therapies that provide safer and more consistent management of hyperkalemia are now available, giving clinicians additional options to optimize evidence-based treatments in patients with HF. This workshop will educate clinicians about the risk factors for developing hyperkalemia, in addition to the latest evidence surrounding the new potassium-binding agents that can optimize evidence-based therapy for HF patients.